Terminal Decline in Physical Function in Older Adults.

J Gerontol A Biol Sci Med Sci

Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Published: January 2024

Background: It is currently unclear whether (and when) physical function exhibits a terminal decline phase, that is, a substantial acceleration of decline in the very last years before death.

Methods: 702 deceased adults aged 70 years and older from the Yale PEP Study provided 4 133 measurements of physical function (Short Physical Performance Battery, SPPB) up to 20 years before death. In addition, continuous gait and chair rise subtest scores (in seconds) were assessed. Generalized mixed regression models with random change points were used to estimate the onset and the steepness of terminal decline in physical function.

Results: Decline accelerated in the last years of life in all 3 measures of physical function. The onset of terminal decline occurred 1 year before death for the SPPB, and at 2.5 and 2.6 years before death for chair rise and gait speed test scores, respectively. Terminal declines in physical function were 6-8 times steeper than pre-terminal declines. Relative to those whose condition leading to death was frailty, participants who died from dementia and cancer had an up to 6 months earlier and 3 months later onset of terminal decline in SPPB, respectively.

Conclusions: Terminal decline in physical function among older adults is comparable to the more established terminal decline phenomenon in cognition. Our results provide additional evidence of late-life rapid decline in physical function due to impending death.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10733182PMC
http://dx.doi.org/10.1093/gerona/glad119DOI Listing

Publication Analysis

Top Keywords

terminal decline
28
physical function
28
decline physical
16
physical
9
decline
9
terminal
8
function older
8
older adults
8
sppb years
8
years death
8

Similar Publications

Beauvoir, Ernaux, and Me: On Age, Disability, and Dying Well.

Cult Med Psychiatry

December 2024

Department of Political Science, Seattle University, Seattle, USA.

Can the fraught relation between disability and aging ever become untangled? What is the place of the catastrophically disabled in a time when giving voice and being seen are significant lodestars of political activism? And what becomes of the caregivers, who often labor in silence, and who hope to work well enough just to get through another day? This essay draws on the memoirs of Simone de Beauvoir, Annie Ernaux, Amy Bloom, and my own experiences to show the complicated imbrications of age, disability, and caretaking. I attempt to demonstrate through these experiences that age and disability, which appear to be intimately woven together, are oftentimes misleadingly connected. I suggest that an ethic of vulnerability, rather, is a more useful heuristic that avoids collapsing the categories of age and disability together.

View Article and Find Full Text PDF

[Making Advance Care Planning a Reality-A Step-by-Step Guide].

Gan To Kagaku Ryoho

December 2024

Dept. of Palliative and Supportive Care, Institute of Medicine, University of Tsukuba.

Advance care planning(ACP)was officially incorporated into Japan's healthcare system in 2018 with the revision of the "Guidelines for the Decision-Making Process in End-of-Life Care"by the Ministry of Health, Labor and Welfare. This revision mandated that the government designated cancer hospitals and comprehensive community care wards establish systems for implementing ACP. Consequently, the implementation and promotion of ACP have become significant issues in the healthcare field.

View Article and Find Full Text PDF

Synaptic dysfunction is one of the earliest cellular defects observed in Alzheimer's disease (AD) and Parkinson's disease (PD), occurring before widespread protein aggregation, neuronal loss, and cognitive decline. While the field has focused on the aggregation of Tau and α-Synuclein (α-Syn), emerging evidence suggests that these proteins may drive presynaptic pathology even before their aggregation. Therefore, understanding the mechanisms by which Tau and α-Syn affect presynaptic terminals offers an opportunity for developing innovative therapeutics aimed at preserving synapses and potentially halting neurodegeneration.

View Article and Find Full Text PDF

Introduction: We investigated whether the cerebellum develops neuropathology that correlates with well-accepted Alzheimer's disease (AD) neuropathological markers and cognitive status.

Methods: We studied cerebellar cytoarchitecture in a cohort (N = 30) of brain donors. In a larger cohort (N = 605), we queried whether the weight of the contents of the posterior fossa (PF), which contains primarily cerebellum, correlated with dementia status.

View Article and Find Full Text PDF

Introduction: CA102N is a novel anticancer drug developed by covalently linking H-Nim (N-(4-Amino-2-phenoxyphenyl methanesulfonamide) to Hyaluronic Acid to target CD44 receptor-rich tumors. The proposed approach seeks to enhance the efficacy and overcome limitations associated with H-Nim, including poor solubility and short half-life.

Methods: The study aimed to evaluate the pharmacokinetics, biodistribution, metabolism, and tumor permeability of [14C] CA102N in xenograft mice following a single intravenous dose of 200 mg/kg.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!